Abstract:Cancer therapy targets specific metabolic pathways or a single gene. This may result in low therapeutic effects due to drug selectivity and drug resistance. Recent studies revealed that the mitochondrial membrane potential and transmembrane permeability of cancerous mitochondria are differed from normal mitochondria. Thus, chemotherapy targeting cancerous mitochondria could be an innovative and competent strategy for cancer therapy. Previously, our work with a novel group of mitochondria targeting small molecules presented promising inhibitory capability toward various cancer cell lines and suppressed adenosine triphosphate (ATP) generation. Therefore, it is critical to understand the anticancer effect and targeting mechanism of these small molecules. This study investigated the inhibitory activity of mitochondria targeting small molecules with human cervical cancer cells - HeLa to further explore their therapeutic potential. HeLa cells were exposed to 10 mu M of syn-thesized compounds and presented elevation in intracellular reactive oxygen species (ROS) level, impaired mitochondrial membrane potential and upregulation of apoptosis as well as necrosis. In vivo, HeLa cell tumor-bearing BALB/c nude mice were treated with mitochondria targeting small molecules for 12 days consecu-tively. Throughout this chemotherapy study, no deleterious side effects nor the appearance of toxicity was observed. Furthermore, mitochondria targeting small molecules treated groups exhibited significant down-regulation with both tumor volume and tumor weight compared to the Doxorubicin (DOX) treated group. Thus, inhibition of mitochondrial ATP synthesis, activation of intracellular ROS production, down-regulation of mitochondrial membrane potential and upregulation of apoptosis and necrosis rates are the indications of cancer therapy. In this work, we examined the anticancer capability of four mitochondria targeting small molecules in vitro and in vivo, and demonstrated a novel therapeutic approach in cancer therapy with tremendous potential.

Rational Design of Mitochondria-Targeted Fluorescent Biosensors for in Vivo Elucidation of the Interaction Between Breast Cancer Metastasis and Mitochondrial Autophagy.

A Mitochondria-targeted AIEgen Labelled with <SUP>18</SUP>F for Breast Cancer Cell Imaging and Therapy

Engineering a tumor-specific and mitochondria targeted fluorescent probe for modulated autophagy and exploited anti-cancer therapy

Targeting the Mitochondria with Pseudo- Stealthy Nanotaxanes to Impair Mitochondrial Biogenesis for Effective Cancer Treatment

Biological Evaluation of Mitochondria Targeting Small Molecules As Potent Anticancer Drugs.

Identification of Mitochondria-Targeting Anticancer Compounds by an in Vitro Strategy.

Targeting cancer cell metabolism with mitochondria-immobilized phosphorescent cyclometalated iridium(iii) complexes.

A Novel Mitochondrial Targeted Hybrid Peptide Modified HPMA Copolymers for Breast Cancer Metastasis Suppression.

Carbon Quantum Dots with Intrinsic Mitochondrial Targeting Ability for Mitochondria-Based Theranostics.

Mitochondria/lysosome Dual-Organelle Labelling Esterase Probe for Monitoring Cell Viability and Evaluating Lung Cancer Drug Efficiency

Mitochondria Targeting and Near-Infrared Fluorescence Imaging of a Novel Heptamethine Cyanine Anticancer Agent.

Identification of a Fluorescent Small-Molecule Enhancer for Therapeutic Autophagy in Colorectal Cancer by Targeting Mitochondrial Protein Translocase TIM44

ZWZ-3, a Fluorescent Probe Targeting Mitochondria for Melanoma Imaging and Therapy

Spotlight on Mitochondrial Health: A Trailblazing Fluorescent Tool for Cancer Detection and Surgical Guidance

Cytochrome C Light-Up Graphene Oxide Nanosensor for the Targeted Self-Monitoring of Mitochondria-Mediated Tumor Cell Death.

A Fluorescent Chemosensor for Long-Term Tracking of Cancer Cell Metastasis and Invasion Via Enzyme-Activated Anchoring

Mitochondrial-targeting Nanoprodrugs to Mutually Reinforce Metabolic Inhibition and Autophagy for Combating Resistant Cancer.

Flower-Like Nanosensors for Photoacoustic-Enhanced Lysosomal Escape and Cytoplasmic Marker-Activated Fluorescence: Enabling High-Contrast Identification and Photothermal Ablation of Minimal Residual Disease in Breast Cancer.

Dehydroberberine Analogue Nanoassemblies for Inducing and Self-Reporting Mitochondrial Dysfunction in Tumor Cells

Targeted Mitochondrial Fluorescence Imaging-Guided Tumor Antimetabolic Therapy with the Imprinted Polymer Nanomedicine Capable of Specifically Recognizing Dihydrofolate Reductase

Optical Monitoring and Treatment of Breast Cancer by a Tumor Hypoxia-Activated Multi-Functional Fluorescent Sensor